Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 2Completed 2Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 44Gynecologic 5Tumor-Agnostic 4Gastrointestinal 2CNS 2Thoracic 1Other solid neoplasm 1Head & Neck 1

Conditions

Neoplasm Metastasis 1Lung Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Carboplatin 182pembrolizumab 157Pemetrexed 132Cisplatin 98Drug Therapy 68Paclitaxel 61osimertinib 55Nivolumab 50Magnetic Resonance Spectroscopy 50Specimen Handling 49durvalumab 48Radiotherapy 48Docetaxel 44atezolizumab 43Etoposide 40Bevacizumab 39tislelizumab 33Blood Specimen Collection 33Radiosurgery 31Gemcitabine 29130-nm albumin-bound paclitaxel 28Immunotherapy 26Immune Checkpoint Inhibitors 24cemiplimab 23Injections 22aflutinib 20Cetuximab 19Biopsy 18Platinum Compounds 17Surgical Procedures, Operative 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × ribociclib × Thoracic × Clear all
NCT06625775 2026-04-13

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Phase 1 Recruiting
392 enrolled
BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡